Update shared on 15 Nov 2025
Fair value Decreased 0.80%Analysts have slightly lowered their price target for Sichuan Kelun Pharmaceutical from ¥40.92 to ¥40.59. This change is due to more cautious assumptions for revenue growth and discount rates, while maintaining a broadly favorable outlook on profitability and valuation metrics.
What's in the News
- Amendments to the articles of association and annexes were approved at the 2nd Extraordinary General Meeting on September 15, 2025 (Key Developments).
- An interim cash dividend for 2025 of CNY 1.26 per ten A shares was approved. The record date is October 20, 2025, and payment is scheduled for October 21, 2025 (Key Developments).
- The company held a Special/Extraordinary Shareholders Meeting on September 15, 2025 in Chengdu. The agenda included amendments to corporate bylaws, adjustment of annual remuneration for the chairman, and a review of the annual profit distribution plan (Key Developments).
Valuation Changes
- Consensus Analyst Price Target: Decreased slightly from CN¥40.92 to CN¥40.59.
- Discount Rate: Lowered modestly from 6.83% to 6.76%.
- Revenue Growth: Adjusted downward from 11.77% to 11.14%.
- Net Profit Margin: Marginally increased from 15.67% to 15.69%.
- Future P/E: Increased slightly from 21.81x to 21.93x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.